FDA Considers New Regulatory Pathways For Some Cellular Products
The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.
You may also be interested in...
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
FDA announced an April hearing to discuss four open draft guidance documents clarifying the regulation of human cells, tissues, or cellular or tissue-based products.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.